Head & neck · 2025
Examining CD103+ Tissue-Resident Memory T Cells in Nasopharyngeal Carcinoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thai Alesha A, Young Richard J, Bressel Mathias, Ma Brigitte B Y, Chua Melvin L K, Soni Pinki, Angel Christopher, Trigos Anna, Rischin Danny, Solomon Benjamin J
Аннотация
BACKGROUND: Tissue-resident memory T cells (TRMs), identified by CD103 expression, play key roles in infection and cancer and often correlate with improved survival in the latter. Their characterization in nasopharyngeal carcinoma (NPC) is of interest due to its viral etiology.
METHODS: NPC tumors from patients treated at Peter MacCallum Cancer Centre (PMCC; 2000-2017) were examined for CD103+, CD8+ T cells, and PD-L1 abundance, correlated with survival, and underwent NanoString transcriptomic analysis. Additional cohorts from Hong Kong and Singapore were assessed for CD103+ intra-tumoral immune cell (ITIC) abundance.
RESULTS: Of the 141 PMCC patients, 29% (n = 30/103) of NPC tumors had high CD103+ ITIC (defined as ≥ 30%) linked with TRM gene expression, immune checkpoints, and upregulated pathways in T-cell activation. Abundance of CD103+ ITIC was not associated with improved survival (PMCC: HR = 0.9, 95% CI: 0.4-2.1) across all cohorts.
CONCLUSIONS: Despite similarities to other virally driven tumors, CD103+ ITIC abundance was not prognostic in NPC, highlighting the need for better characterization of TRMs subpopulations.
METHODS: NPC tumors from patients treated at Peter MacCallum Cancer Centre (PMCC; 2000-2017) were examined for CD103+, CD8+ T cells, and PD-L1 abundance, correlated with survival, and underwent NanoString transcriptomic analysis. Additional cohorts from Hong Kong and Singapore were assessed for CD103+ intra-tumoral immune cell (ITIC) abundance.
RESULTS: Of the 141 PMCC patients, 29% (n = 30/103) of NPC tumors had high CD103+ ITIC (defined as ≥ 30%) linked with TRM gene expression, immune checkpoints, and upregulated pathways in T-cell activation. Abundance of CD103+ ITIC was not associated with improved survival (PMCC: HR = 0.9, 95% CI: 0.4-2.1) across all cohorts.
CONCLUSIONS: Despite similarities to other virally driven tumors, CD103+ ITIC abundance was not prognostic in NPC, highlighting the need for better characterization of TRMs subpopulations.